[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"non-hodgkin39s-lymphoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:non-hodgkin39s-lymphoma":58},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,41,82,98,114],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100604292","evaluation-of-chemotherapy-induced-cognitive-disorders-during-the-treatment-of-hematological-malignancies-100604292",false,"NCT07147621","Evaluation of Chemotherapy-induced Cognitive Disorders During the Treatment of Hematological Malignancies","HematoBrain","Inclusion Criteria:\n\n* Patient group inclusion criteria:\n\n  * adult patient with acute myeloid leukemia, Hodgkin's lymphoma, or non-Hodgkin's lymphoma;\n  * patient receiving a fixed-duration first-line chemotherapy;\n  * patient affiliated or beneficiary of a social security scheme; .signed inform consent form.\n* Control group inclusion criteria:\n\n  * adult;\n  * patient's relative (spouse, brother, sister, friend, etc.);\n  * less than 5 years of difference with the patient;\n  * same educational level (\\\u003C baccalaureate\u002Fhigh school degree, baccalaureate\u002Fhigh school degree level, 2-year university degree, \\> 2-year university degree);\n  * person affiliated or beneficiary of a social security scheme;\n  * signed informed consent form\n\nExclusion Criteria:\n\n* Patient group exclusion criteria:\n\n  * no patient's relative for the control group;\n  * known or suspective cognitive disorders prior to chemotherapy;\n  * history of severe neurological or psychiatric disorders (e.g., severe depression); .previous chemotherapy;\n  * previous brain radiotherapy;\n  * ongoing treatments affecting cognition;\n  * patient unable to read;\n  * patient not speaking French;\n  * person deprived of liberty by judicial or administrative decision;\n  * person under forced psychiatric care;\n  * person under legal protection measures;\n  * person unable to express consent; .pregnant or breastfeeding woman.\n* Control group exclusion criteria:\n\n  * known or suspected cognitive disorders;\n  * history of severe neurological or psychiatric disorder (e.g., severe depression); .previous chemotherapy;\n  * previous brain radiotherapy;\n  * ongoing treatments affecting cognition;\n  * person unable to read;\n  * person not speaking French;\n  * person deprived of liberty by judicial or administrative decision;\n  * person under forced psychiatric care;\n  * person under legal protection measures;\n  * person unable to express consent;\n  * pregnant or breastfeeding woman.\"",true,"ALL","18 Years",{"count":20,"type":21},120,"ESTIMATED","OBSERVATIONAL","Chemotherapy-induced cognitive disorders, such as memory problems, slowness of execution, inability to concentrate, and language difficulties, are sequelae that occur in patients undergoing chemotherapy or who have received chemotherapy. These symptoms lead to a degradation of the patients' quality of life and can have a significant social and familial impact. They are most commonly described in solid oncology, particularly in patients with breast cancer. Data about patients with hematological malignancies are scarce, but they seem to show the same phenomenon as in solid oncology. Indeed, many chemotherapies are used both in hematology and solid oncology and may therefore cause similar effects on cognition. Additionally, due to their mechanism of action, some chemotherapies specifically used in hematology could induce cognitive disorders. Hematology-treated patients are probably also affected by these disorders and may consequently experience a reduced quality of life.\n\nThe objective of this study is to assess the changes in cognitive functions in patients receiving chemotherapy for the treatment of hematological malignancies, using neuropsychological tests and a self-administered questionnaire, compared to a control group, as well as their potential impact on quality of life, fatigue, anxiety, and depression.",[25,26,27],"Acute Myeloid Leukemia","Hodgkin's Lymphoma","Non-Hodgkin's Lymphoma","RECRUITING","2026-03-03",{"date":31,"type":32},"2026-03-06","ACTUAL",{"date":34,"type":32},"2026-02-26",{"date":36,"type":21},"2027-10",{"name":38,"class":39},"University Hospital, Angers","OTHER_GOV",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":54,"conditions":55,"keywords":59,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":81},"100608479","phase-2-role-of-antibiotic-therapy-or-immunoglobulin-on-infections-in-haematology-immunoglobulin-stopping-or-extension-stop-ig-100608479","NCT07202091","Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig)","Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy (Stop-Ig)","Inclusion Criteria:\n\n1. Patients must be receiving Ig (IV or subcutaneous - SCIg) replacement for prevention of bacterial infections due to hypogammaglobulinaemia for at least 6 consecutive months.\n2. Patient is eligible for trial of Ig cessation in the opinion of the treating clinician and local investigator.\n3. Patient is willing and able to comply with each of the treatment arms.\n\nExclusion Criteria:\n\n1. Prior or planned allogeneic haematopoietic stem cell transplantation.\n2. Major infection (Grade 3 or higher) in preceding 3 months, and\u002For current active infection requiring systemic antimicrobial treatment.\n3. Already receiving systemic antibiotic prophylaxis for the purpose of preventing bacterial infection (NB: patients may receive antiviral, antifungal and PJP prophylaxis).\n4. Intolerance of all trial antibiotic options in either arm A or arm B.\n5. Communication, compliance or logistical issues that are likely to limit patient's ability to take prophylactic or emergency antibiotics, or to obtain urgent medical attention for symptoms of infection.\n6. Pregnant or breastfeeding.\n7. Severe renal impairment (estimated or measured creatinine clearance of \\\u003C 30 mL\u002Fmin).\n8. Previous splenectomy.\n9. Previous participation in this domain.\n10. Treating team deems enrolment in the domain is not in the best interests of the patient.",{"count":49,"type":21},900,"INTERVENTIONAL",[52,53],"PHASE2","PHASE3","This study is being conducted to find out how safe and effective different strategies of infection prevention are in comparison to each other, for preventing infection in patients with blood cancers. The best way to find out this information is to directly compare the effect of different treatment strategies in patients with blood cancers. We want to know how these different treatments impact on your health and your use of healthcare services.\n\nThis research project uses an Adaptive Platform Design. This design allows the researchers to compare multiple infection prevention strategies within the same trial at the same time (rather than running separate trials), to analyse results as the trial occurs and to add new research questions during the course of the trial.\n\nThe treatments that you may receive as part of the study will be determined by which domain(s) of the platform you participate in. By combining data collected within each domain as part of the platform, the researchers can investigate and compare treatment strategies and infection outcomes across a broader range of participants.",[56,57,58],"Myeloma","Leukemia","Non Hodgkin's Lymphoma",[60,61,62,63,64,65,66,67,68,69,70],"immunoglobulin","antibiotics","myeloma","leukaemia","lymphoma","non Hodgkins","infection","infections","blood","cancer","haematology","2025-10-01",{"date":73,"type":32},"2025-10-07",{"date":75,"type":32},"2025-05-06",{"date":77,"type":21},"2027-03-31",{"name":79,"class":80},"Monash University","OTHER",3,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":50,"phases":90,"briefSummary":54,"conditions":91,"keywords":92,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":93,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":97,"locationsCount":81},"100608478","phase-2-role-of-antibiotic-therapy-or-immunoglobulin-on-infections-in-haematology-starting-immunoglobulin-start-ig-100608478","NCT07202078","Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig)","Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy (Start Ig)","Inclusion Criteria:\n\n* None.\n\nExclusion Criteria:\n\n1. Prior or planned allogeneic haematopoietic stem cell transplantation.\n2. Already receiving systemic antibiotic prophylaxis for the purpose of preventing bacterial infection (NB: patients may receive antiviral, antifungal and PJP prophylaxis).\n3. Received immunoglobulin replacement in the preceding three months.\n4. Objection to receiving immunoglobulin products.\n5. Known history of IgA deficiency with anti-IgA.\n6. History of severe allergy to immunoglobulin products.\n7. Current active infection requiring systemic antibiotics.\n8. Allergy or intolerance of all domain antibiotic options.\n9. Pregnant or breastfeeding.\n10. Severe renal impairment (estimated or measured creatinine clearance of \\\u003C 30 mL\u002Fmin).\n11. Previous splenectomy.\n12. Previous participation in this domain.\n13. Treating team deems enrolment in the domain is not in the best interest of the patient.",{"count":49,"type":21},[52,53],[56,58,57],[60,61,62,63,64,65,66,67,68,69,70],{"date":73,"type":32},{"date":95,"type":32},"2025-05-07",{"date":77,"type":21},{"name":79,"class":80},{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":50,"phases":106,"briefSummary":54,"conditions":107,"keywords":108,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":109,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":113,"locationsCount":81},"100608477","phase-2-role-of-antibiotic-therapy-or-immunoglobulin-on-infections-in-haematology-dosing-immunoglobulin-dose-ig-100608477","NCT07202065","Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig)","Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy (Dose-Ig)","Inclusion Criteria:\n\n1. Patients must be receiving IVIg replacement at standard dose for prevention of bacterial infections due to hypogammaglobulinaemia for at least 6 consecutive months.\n2. Patient is not eligible for trial of Ig cessation in the opinion of the treating clinician and local investigator.\n\nExclusion Criteria:\n\n1. Prior or planned allogeneic haematopoietic stem cell transplantation.\n2. Major infection (Grade 3 or higher) in preceding 3 months, and or current active infection requiring systemic antimicrobial treatment.\n3. Previous splenectomy.\n4. Known history of bronchiectasis.\n5. Previous participation in this domain.\n6. Treating team deems enrolment in the domain is not in the best interest of the patient.",{"count":49,"type":21},[52,53],[56,58,57],[60,61,62,63,64,65,66,67,68,69,70],{"date":73,"type":32},{"date":111,"type":32},"2025-04-28",{"date":77,"type":21},{"name":79,"class":80},{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":121,"targetDuration":123,"studyType":22,"phases":4,"briefSummary":124,"conditions":125,"keywords":127,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":4},"100571434","efficacy-of-68ga-pentixafor-petmr-in-detecting-non-hodgkin-lymphoma-and-multiple-myeloma-lesions-100571434","NCT06720207","Efficacy of 68Ga-Pentixafor PET\u002FMR in Detecting Non-Hodgkin Lymphoma and Multiple Myeloma Lesions","Exploratory Study on the Efficacy of 68Ga-Pentixafor PET\u002FMR in Detecting Lesions in Non-Hodgkin Lymphoma and Multiple Myeloma","Inclusion Criteria:\n\n1. Age of 18 years or older\n2. ECOG \\\u003C 2\n3. Newly diagnosed patients with NHL and MM who have been confirmed or are highly suspected based on pathological examination\n4. Completion of 18F-FDG PET\u002FCT or PET\u002FMR imaging within the past week in our department\n\nExclusion Criteria:\n\n1. Pregnant and breastfeeding women;\n2. Individuals with severe hepatic and renal failure;\n3. Patients with concurrent malignancies;\n4. Individuals unable to remain supine for a duration of 30 minutes to complete the examination;\n5. Patients with diagnosed claustrophobia;\n6. Patients containing metallic implants;\n7. Individuals deemed unsuitable for participation in clinical trials by researchers.",{"count":122,"type":21},30,"3 Years","In this study, the investigators intend to utilize 68Ga-Pentixafor Positron Emission Tomography（PET） imaging for patients diagnosed with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). The investigators will compare the imaging results with those obtained from 18F-FDG imaging, and a correlation analysis will be performed to assess progression-free survival among patients. This analysis aims to evaluate the diagnostic efficacy and the potential for early prediction of treatment efficacy associated with 68Ga-Pentixafor in these specific conditions.",[58,126],"Multiple Myeloma (MM)",[128,58,129],"PET\u002FMR","multiple myeloma","NOT_YET_RECRUITING","2025-06-24",{"date":133,"type":32},"2025-06-27",{"date":135,"type":21},"2025-07-01",{"date":137,"type":21},"2027-07-31",{"name":139,"class":80},"Shanghai East Hospital"]